{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:00:44Z","timestamp":1794261644190,"version":"4.9.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13161-5","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:36:17Z","timestamp":1774488977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic factors for mortality in critically ill patients with infections caused by carbapenem-resistant gram-negative pathogens treated with ceftazidime\u2013avibactam: a multicenter retrospective study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9036-0269","authenticated-orcid":false,"given":"Mustafa Serhat","family":"\u015eahino\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-3168","authenticated-orcid":false,"given":"Selcen \u00d6zer","family":"K\u00f6kk\u0131z\u0131l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1245-3221","authenticated-orcid":false,"given":"Arzu","family":"Tarak\u00e7\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-2477","authenticated-orcid":false,"given":"Sevil","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3428-6137","authenticated-orcid":false,"given":"Mustafa","family":"U\u011fuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1827-4862","authenticated-orcid":false,"given":"Elif","family":"Erta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-0474","authenticated-orcid":false,"given":"Oya \u00d6zlem Eren","family":"Kutsoylu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"13161_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1473-3099(16)30257-2","volume":"17","author":"H Grundmann","year":"2017","unstructured":"Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasevi\u0107 AT, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153\u201363. https:\/\/doi.org\/10.1016\/S1473-3099(16)30257-2.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"13161_CR2","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","volume":"67","author":"SS Kadri","year":"2018","unstructured":"Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, et al. Difficult-to-Treat Resistance in Gram-Negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018;67(12):1803\u201314. https:\/\/doi.org\/10.1093\/cid\/ciy378.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"13161_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3.","journal-title":"Lancet Infect Dis"},{"key":"13161_CR4","unstructured":"World Health Organisation (WHO). Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics(2017). Reference Number: WHO\/EMP\/IAU\/2017.12."},{"key":"13161_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by the European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28:521\u201347. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"13161_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M, Ceftazidime-Avibactam. A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs. 2018;78(6):675\u201392. https:\/\/doi.org\/10.1007\/s40265-018-0902-x.","journal-title":"Drugs"},{"key":"13161_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijantimicag.2015.05.003","volume":"46","author":"JL Liscio","year":"2015","unstructured":"Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane\/tazobactam and ceftazidime\/avibactam: Two novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015;46:266\u201371. https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.05.003.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"13161_CR8","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1007\/s11033-020-05651-9","volume":"47","author":"P Behzadi","year":"2020","unstructured":"Behzadi P, Garc\u00eda-Perdomo HA, Karpi\u0144ski TM, Issakhanian L. Metallo-\u00df-lactamases: a review. Mol Biol Rep. 2020;47(8):6281\u201394. https:\/\/doi.org\/10.1007\/s11033-020-05651-9.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"13161_CR9","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s40121-021-00506-7","volume":"10","author":"JE Mazuski","year":"2021","unstructured":"Mazuski JE, Wagenlehner F, Torres A, Carmeli Y, Chow JW, Wajsbrot D, et al. Clinical and microbiological outcomes of ceftazidime\u2013avibactam treatment in adults with gram-negative bacteremia: a subset analysis from the phase 3 clinical trial program. Infect Dis Ther. 2021;10(4):2399\u2013414. https:\/\/doi.org\/10.1007\/s40121-021-00506-7.","journal-title":"Infect Dis Ther"},{"key":"13161_CR10","unstructured":"List of prescribing rules for systemic antimicrobials and other medicines. Annex-4-E. Health implementation communiqu\u00e9. Turkish Pharmacists Association. (2023). Accessed: August 25, 2023: latest\/700\/sut20190904."},{"key":"13161_CR11","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"JL Vincent","year":"2009","unstructured":"Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, EPIC II Group of Investigators, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323\u20139. https:\/\/doi.org\/10.1001\/jama.2009.1754.","journal-title":"JAMA"},{"key":"13161_CR12","doi-asserted-by":"publisher","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW. The pharmacokinetics and pharmacodynamics study group of the European society of clinical microbiology and infectious diseases. On behalf of the International Society of Anti-infective Pharmacology and. 2014. Individualized antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498 \u2013\u2009509. https:\/\/doi.org\/10.1016\/S1473-3099(14)70036-2.","DOI":"10.1016\/S1473-3099(14)70036-2"},{"key":"13161_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/DHPS.S339808","volume":"14","author":"TZ Lin","year":"2022","unstructured":"Lin TZ, Jayasvasti I, Tiraphat S, Pengpid S, Jayasvasti M, Borriharn P. The Predictors Influencing the Rational Use of Antibiotics Among Public Sector: A Community-Based Survey in Thailand. Drug Healthc Patient Saf. 2022;14:27\u201336. https:\/\/doi.org\/10.2147\/DHPS.S339808.","journal-title":"Drug Healthc Patient Saf"},{"key":"13161_CR14","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.2147\/IDR.S422545","volume":"16","author":"J Yu","year":"2023","unstructured":"Yu J, Zuo W, Fan H, Wu J, Qiao L, Yang B, et al. Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Bacteria Infections: A Real-World Experience in the ICU. Infect Drug Resist. 2023;16:6209\u201316. https:\/\/doi.org\/10.2147\/IDR.S422545.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"13161_CR15","doi-asserted-by":"publisher","first-page":"106536","DOI":"10.1016\/j.ijantimicag.2022.106536","volume":"59","author":"B Baland\u00edn","year":"2022","unstructured":"Baland\u00edn B, Ballesteros D, Pintado V, Soriano-Cuesta C, Cid-Tovar I, Sancho-Gonz\u00e1lez M, et al. Multicentre study of ceftazidime\/avibactam for Gram-negative bacteria infections in critically ill patients. Int J Antimicrob Agents. 2022;59(3):106536. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106536.","journal-title":"Int J Antimicrob Agents"},{"key":"13161_CR16","doi-asserted-by":"publisher","unstructured":"\u00d6nal U, T\u00fczemen \u00dc, Kaya PK, \u0130\u015f\u00e7imen R, Girgin NK, \u00d6zak\u0131n C, et al. OXA-48 Dominance meets ceftazidime-avibactam: a battle against life-threatening carbapenem-resistant klebsiella pneumoniae infections in the intensive care unit. Cureus 15(10): e46780. https:\/\/doi.org\/10.7759\/cureus.46780.","DOI":"10.7759\/cureus.46780"},{"key":"13161_CR17","doi-asserted-by":"publisher","unstructured":"Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by klebsiella pneumoniae carbapenemase\u2013producing K. pneumoniae, clinical infectious diseases. 2019 Feb 1;68(3):355\u201364. https:\/\/doi.org\/10.1093\/cid\/ciy492.","DOI":"10.1093\/cid\/ciy492"},{"issue":"5","key":"13161_CR18","doi-asserted-by":"publisher","first-page":"dlac104","DOI":"10.1093\/jacamr\/dlac104","volume":"4","author":"H Alqahtani","year":"2022","unstructured":"Alqahtani H, Alghamdi A, Alobaidallah N, Alfayez A, Almousa R, Albagli R, et al. Evaluation of ceftazidime\/avibactam for treatment of carbapenemase-producing carbapenem-resistant Enterobacterales with OXA-48 and\/or NDM genes with or without combination therapy. JAC Antimicrob Resist. 2022;4(5):dlac104. https:\/\/doi.org\/10.1093\/jacamr\/dlac104.","journal-title":"JAC Antimicrob Resist"},{"key":"13161_CR19","doi-asserted-by":"publisher","unstructured":"Zheng G, Zhang J, Wang B, Cai J, Wang L, Hou K, et al. Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Ther. 2021;10(3):1699\u20131713. https:\/\/doi.org\/10.1007\/s40121-021-00479-7. Epub 2021 Jul 9. Erratum in: Infect Dis Ther. 2022;11(2):935\u2013936. https:\/\/doi.org\/10.1007\/s40121-021-00569-6.","DOI":"10.1007\/s40121-021-00479-7"},{"key":"13161_CR20","doi-asserted-by":"publisher","first-page":"9767313","DOI":"10.1155\/2019\/9767313","volume":"2019","author":"Y Li","year":"2019","unstructured":"Li Y, Shen H, Zhu C, Yu Y. Carbapenem-Resistant Klebsiella pneumoniae Infections among ICU Admission Patients in Central China: Prevalence and Prediction Model. Biomed Res Int. 2019;2019:9767313. https:\/\/doi.org\/10.1155\/2019\/9767313.","journal-title":"Biomed Res Int"},{"key":"13161_CR21","doi-asserted-by":"publisher","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149-60. https:\/\/doi.org\/10.3758\/BRM.41.4.1149. PMID: 19897823.","DOI":"10.3758\/BRM.41.4.1149"},{"key":"13161_CR22","unstructured":"CDC: people who are immunocompromised. (2023). Accessed: July 17, 2023: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-who-areimmunocompromised.html."},{"issue":"9","key":"13161_CR23","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/cid\/ciz528","volume":"70","author":"H Henderson","year":"2020","unstructured":"Henderson H, Luterbach CL, Cober E, Richter SS, Salata RA, Kalayjian RC, et al. The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections. Clin Infect Dis. 2020;70(9):1826\u201333. https:\/\/doi.org\/10.1093\/cid\/ciz528.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"13161_CR24","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245\u201351.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"13161_CR25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801\u201310. https:\/\/doi.org\/10.1001\/jama.2016.0287.","journal-title":"JAMA"},{"key":"13161_CR26","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 10.0. 2020. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_10.0_Breakpoint_Tables.pdf."},{"key":"13161_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijantimicag.2018.03.018","volume":"52","author":"R Recio","year":"2018","unstructured":"Recio R, Villa J, Viedma E, Orellana M\u00c1, Lora-Tamayo J, Chaves F. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: facing the perfect storm. Int J Antimicrob Agents. 2018;52:172\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.03.018.","journal-title":"Int J Antimicrob Agents"},{"key":"13161_CR28","doi-asserted-by":"publisher","unstructured":"\u015eim\u015fek Bozok T, Bozok T, \u015eahino\u011flu MS, Kaya H, Horasan E\u015e, Kaya A. (2024). Bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae: analysis of risk factors, treatment responses and mortality. Infect Dis (Lond). 2025;57(4):350\u2013360. https:\/\/doi.org\/10.1080\/23744235.2024.2436991.","DOI":"10.1080\/23744235.2024.2436991"},{"key":"13161_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jgar.2019.01.032","volume":"18","author":"A Acar","year":"2019","unstructured":"Acar A, Karaahmeto\u011flu G, Akal\u0131n H, Altay AF. Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: A meta-analysis. J Glob Antimicrob Resist. 2019;18:64\u201370. https:\/\/doi.org\/10.1016\/j.jgar.2019.01.032.","journal-title":"J Glob Antimicrob Resist"},{"key":"13161_CR30","unstructured":"Ministry of Health, Republic of T\u00fcrkiye. National Healthcare-Associated Infections Surveillance Network (USHIESA) summary report 2023. Ankara: General Directorate of Public Health, Department of Infectious Diseases and Early Warning; 2023. https:\/\/hsgm.saglik.gov.tr\/depo\/birimler\/bulasici-hastaliklar-ve-erken-uyari-db\/Dokumanlar\/Raporlar\/USHIESA_OZET_RAPOR_2023_03.07.2024.pdf."},{"key":"13161_CR31","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis 2024 Aug 7:ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"issue":"1","key":"13161_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","volume":"24","author":"M Falcone","year":"2020","unstructured":"Falcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24(1):29. https:\/\/doi.org\/10.1186\/s13054-020-2742-9.","journal-title":"Crit Care"},{"issue":"2","key":"13161_CR33","doi-asserted-by":"publisher","first-page":"e01964","DOI":"10.1128\/AAC.01964-16","volume":"61","author":"E Temkin","year":"2017","unstructured":"Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, et al. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. Antimicrob Agents Chemother. 2017;61(2):e01964\u201316. https:\/\/doi.org\/10.1128\/AAC.01964-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"13161_CR34","doi-asserted-by":"publisher","first-page":"ofz522","DOI":"10.1093\/ofid\/ofz522","volume":"6","author":"SCJ Jorgensen","year":"2019","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, et al. Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infect Dis. 2019;6(12):ofz522. https:\/\/doi.org\/10.1093\/ofid\/ofz522.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"13161_CR35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40121-023-00762-9","volume":"12","author":"A Soriano","year":"2023","unstructured":"Soriano A, Montravers P, Bassetti M, Klyasova G, Daikos G, Irani P, et al. The Use and Effectiveness of Ceftazidime-Avibactam in Real-World Clinical Practice: EZTEAM Study. Infect Dis Ther. 2023;12(3):891\u2013917. https:\/\/doi.org\/10.1007\/s40121-023-00762-9.","journal-title":"Infect Dis Ther"},{"issue":"9","key":"13161_CR36","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cid\/ciab176","volume":"73","author":"M Tumbarello","year":"2021","unstructured":"Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, et al. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clin Infect Dis. 2021;73(9):1664\u201376. https:\/\/doi.org\/10.1093\/cid\/ciab176.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"13161_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10096-023-04577-x","volume":"42","author":"M Boattini","year":"2023","unstructured":"Boattini M, Bianco G, Charrier L, Comini S, Iannaccone M, Almeida A, et al. Rapid diagnostics and ceftazidime\/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy. Eur J Clin Microbiol Infect Dis. 2023;42(4):431\u20139. https:\/\/doi.org\/10.1007\/s10096-023-04577-x.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"13161_CR38","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s15010-024-02277-y","volume":"52","author":"W Hsu","year":"2024","unstructured":"Hsu W, Chuang MH, Tsai WW, Lai CC, Lai HY, Tang HJ. Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis. Infection. 2024;52(5):2029\u201342. https:\/\/doi.org\/10.1007\/s15010-024-02277-y.","journal-title":"Infection"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13161-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13161-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13161-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:39:44Z","timestamp":1777937984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13161-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13161"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13161-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation\n                      (institutional and national)\n                      and with the Helsinki Declaration of 1975, as revised in 2008. This study was approved by the Dokuz Eylul University Non-Interventional Research Ethics Committee (decision number: 2023\/11\u2009\u2212\u200903; file number: 7973-GOA). As the study was conducted retrospectively using anonymized data, obtaining informed consent from individual participants was not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Presented at 13th T\u00fcrkiye EKMUD congress as an oral presentation. The original article is not under consideration by another publication, and its substance, tables, or figures have not been published previously and will only be published elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"892"}}